<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301353</url>
  </required_header>
  <id_info>
    <org_study_id>Phytos QLRT-2000-00431-WP3</org_study_id>
    <nct_id>NCT00301353</nct_id>
  </id_info>
  <brief_title>Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women</brief_title>
  <official_title>Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TNO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Research on Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TNO</source>
  <brief_summary>
    <textblock>
      Osteoporosis is a major health problem. It was hypothesized that isoflavone-containing&#xD;
      products may be a potential alternative to HRT for preventing bone loss during the menopausal&#xD;
      transition. We investigated whether one-year consumption of isoflavone-enriched foods&#xD;
      affected bone mineral density, bone metabolism and hormonal status in early postmenopausal&#xD;
      women in a randomized double-blind, placebo controlled parallel multi-centre trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred and thirty-seven healthy early post-menopausal women (age 53 ± 3 y; time since&#xD;
      last menses 33 ± 15 months) consumed isoflavone-enriched foods providing a mean daily intake&#xD;
      of 110 mg isoflavone aglycones or control products for 1 yr whilst continuing their habitual&#xD;
      diet and lifestyle. Outcome measures included bone mineral density of lumbar spine and total&#xD;
      body, markers for bone formation and bone resorption, hormones, isoflavones in plasma and&#xD;
      urine, safety parameters and reporting of adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>July 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density of total body and lumbar spine (DXA)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and urine markers for bone formation (ALP, PINP) and bone resorption (DPD, PYD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormones (estradiol, FSH, LH, SHBG)</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflavones-enriched foods</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy as assessed by the:&#xD;
&#xD;
               -  health and lifestyle questionnaire&#xD;
&#xD;
               -  physical examination&#xD;
&#xD;
               -  results of the pre-study laboratory tests&#xD;
&#xD;
          2. Caucasian women&#xD;
&#xD;
          3. Postmenopausal (≥12 - ≤60 months since last menses), determined by&#xD;
&#xD;
               -  interview&#xD;
&#xD;
               -  FSH level ≥ 20 IU/l&#xD;
&#xD;
          4. Body Mass Index (BMI) ≥22 - ≤29 kg/m2&#xD;
&#xD;
          5. Voluntary participation&#xD;
&#xD;
          6. Having given their written informed consent&#xD;
&#xD;
          7. Willing to comply with the study procedures&#xD;
&#xD;
          8. Willing to accept use of all nameless data, including publication and the confidential&#xD;
             use and storage of all data&#xD;
&#xD;
          9. Willing to accept the disclosure of the financial benefit of participation in the&#xD;
             study to the authorities concerned&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in any clinical trial including blood sampling and/or administration of&#xD;
             products up to 90 days before Day 01 of this study&#xD;
&#xD;
          2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this&#xD;
             study, including no blood sampling and/or oral, intravenous, inhalatory administration&#xD;
             of products&#xD;
&#xD;
          3. Osteoporosis, determined by&#xD;
&#xD;
               -  Questionnaire (spontaneous bone fractures, use of medication to treat&#xD;
                  osteoporosis)&#xD;
&#xD;
               -  DXA scans of the lumbar spine between day -14 and day 1 of the study; exclusion&#xD;
                  threshold is set at -2z score of BMD&#xD;
&#xD;
          4. Severe scoliosis (curvature of the spine) that could interfere with the ability of the&#xD;
             subject to go through the DXA scanning procedure and/or with a correct reading of the&#xD;
             DXA scans&#xD;
&#xD;
          5. Having a history of medical or surgical events that may significantly affect the study&#xD;
             outcome, including:&#xD;
&#xD;
               -  surgical menopause (including hysterectomy)&#xD;
&#xD;
               -  antecedents and high familiar incidence of breast and/or endometrial cancer&#xD;
&#xD;
               -  gastrointestinal disease (Crohn's, short bowel syndrome, coeliac disease,&#xD;
                  gastroenteritis episodes the month before the start of the study)&#xD;
&#xD;
               -  hepatic disease (acute or viral hepatitis, chronic hepatitis)&#xD;
&#xD;
               -  cardiovascular disease and thrombosis&#xD;
&#xD;
               -  impaired renal function&#xD;
&#xD;
               -  severe immune disease&#xD;
&#xD;
               -  endocrine diseases (hyperthyroidism, hyperparathyroidism, IDDM, NIDDM)&#xD;
&#xD;
          6. Food allergy as reported by the subject (with special emphasis on soy products) and&#xD;
             reported allergy for sunscreen products&#xD;
&#xD;
          7. Use of concomitant medication including&#xD;
&#xD;
               -  Hormonal replacement therapy (during the study and within the last 6 months&#xD;
                  before day 01 of the study)&#xD;
&#xD;
               -  Current use of corticosteroids (including Aerosol therapy) or past use for more&#xD;
                  than 10 days within the last 6 months&#xD;
&#xD;
               -  Osteoporosis treatment (biphosphonates, SERM's, calcitonin, injectable PTH)&#xD;
&#xD;
               -  Other medications known to affect bone metabolism (statins). Use of antibiotics&#xD;
                  will be carefully recorded.&#xD;
&#xD;
          8. Change in smoking habits for the last 2 months&#xD;
&#xD;
          9. Alcohol consumption &gt; 21 units (drinks)/week&#xD;
&#xD;
         10. Reported unexplained weight loss or gain of &gt; 5 % of usual body weight in the month&#xD;
             prior to the pre-study screening&#xD;
&#xD;
         11. Reported slimming or medically prescribed diet&#xD;
&#xD;
         12. Professional sportswomen (&gt; 10 hours extensive sports/week)&#xD;
&#xD;
         13. Reported vegan, vegetarian, macrobiotic food intake&#xD;
&#xD;
         14. Regular intake of soy based foods (&gt;2 servings per week). Participation is possible&#xD;
             when the subject is prepared to stop consumption from screening until the end of the&#xD;
             study&#xD;
&#xD;
         15. Taking supplements containing isoflavones, in the 3 months prior to enrolment and&#xD;
             during the study. Subjects should not start taking calcium and vitamin D supplements&#xD;
             during the study. However, subjects who already take calcium and vitamin D supplements&#xD;
             should maintain this intake during the study&#xD;
&#xD;
         16. Recent blood or plasma donation (&lt;1 month prior to the start of the study)&#xD;
&#xD;
         17. Not willing to stop blood or plasma donation during the study&#xD;
&#xD;
         18. TNO Nutrition and Food Research personnel, their partner and their first and second&#xD;
             generation relatives&#xD;
&#xD;
         19. Not having a general practitioner&#xD;
&#xD;
         20. Not willing to accept information-transfer concerning participation in the study, or&#xD;
             information regarding his/her health. For example, laboratory results, findings at&#xD;
             health and lifestyle questionnaire interview, or physical examination and eventual&#xD;
             adverse events communicated to and from their general practitioner&#xD;
&#xD;
         21. Mental status incompatible with the proper conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Brink, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TNO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute National de la Recherche Agronomique</name>
      <address>
        <city>Saint-Genes Champanelle</city>
        <zip>63122</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Research on Food an Nutrition</name>
      <address>
        <city>Rome</city>
        <zip>00178</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TNO Quality of Life</name>
      <address>
        <city>Zeist</city>
        <zip>3700 AJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2006</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <keyword>early menopause</keyword>
  <keyword>isoflavones/phyto-estrogens</keyword>
  <keyword>bone metabolism</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

